March 31, 2014 / 10:31 AM / 4 years ago

Prana says drug fails Alzheimer's disease study

March 31 (Reuters) - Prana Biotechnology Ltd said its experimental drug to treat Alzheimer’s disease failed to meet the main goal of a mid-stage study in patients with a mild form of the condition.

The company’s shares fell about 38 percent to $6.13 in premarket trade on Monday.

Prana said the drug did not show a statistically significant reduction in the levels of beta-amyloid plaques in the brain, which are considered a major cause of the disease’s progression. (Reporting by Vrinda Manocha in Bangalore; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below